/Charles%20River%20Laboratories%20International%20Inc_%20logo-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. Valued at $9.1 billion by market cap, the company offers animal research models in research and development for new drugs, devices, and therapies, serving pharmaceutical and biotechnology companies, hospitals, and academic institutions worldwide. The pharmaceutical company is expected to announce its fiscal first-quarter earnings for 2026 before the market opens on Thursday, May 7.
Ahead of the event, analysts expect CRL to report a profit of $1.96 per share on a diluted basis, down 16.2% from $2.34 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.